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Introduction
Pharmacotherapy for neurodegenerative disorders is hampered by the inability of most small molecules to cross the blood-brain barrier (BBB) and the blood spinal cord barrier (BSCB). Three main cell types, the endothelial cells, pericytes, and astrocytes form the BBB and BSCB and protect the central nervous system (CNS) by restricting diffusion of many solutes into the cerebrospinal fluid. This is achieved through a combination of tight junctions formed by the endothelial cells, a lack of pinocytotic activity, and efflux transporters. The predominant efflux transporters, P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP, ABCG2), are members of the ATP-binding cassette (ABC) class. They are expressed on the apical surface of endothelial cell and function to intercept drugs entering the CNS capillary cells and transport them against their concentration gradient back into the blood (Schinkel et al., 1994 (Schinkel et al., , 1996 Rao et al., 1999; Cherry et al., 2013) . The BBB and BSCB are fully formed (Saunders et al., 2012) and P-gp and BCRP transporters are correctly localized well before birth (Daood et al., 2008) . While there are some differences between the BBB and BSCB including lower protein levels of tight junction markers and increases to permeability there are no significant differences in Pgp levels (Bartanusz et al., 2011) .
Spinal muscular atrophy (SMA) is a motor neuron disorder caused by deletions and other mutations of the highly conserved survival of motor neuron-1 gene (SMN1) with retention of the nearly identical paralog, SMN2. A promising approach to treating SMA is to increase levels of SMN protein by reducing its degradation through the ubiquitin proteasome system (Lefebvre et al., 1995; McAndrew et al., 1997; Kwon et al., 2013) . We have previously shown that inhibition of the proteasome by the inhibitor bortezomib increases SMN protein levels in cultured cells and in peripheral tissues of SMA mice. Long term bortezomib treatment resulted in an improvement in motor function in SMA mice compared with vehicle treated animals; however survival was unaffected (Kwon et al., 2011) . Pre-clinical studies have shown that bortezomib is unable to penetrate into the CNS, impeding its use for treating SMA and other neurological disorders (Nakamura et al., 2007; Rumpold et al., 2007; Lu et al., 2010) . To overcome bortezomib's low biodistribution in the CNS, we hypothesized that pre-treatment with an ABC transporter inhibitor would prevent bortezomib's efflux at the blood-brain and -spinal cord barriers.
In this study we used overexpress cell lines, genetic mouse models, and systemic administration of an inhibitor to demonstrate that bortezomib is a substrate of P-gp. Using mass spectrometry we were able to detect bortezomib in the CNS of SMA model mice coadministered with a P-gp inhibitor tariquidar. SMN levels were also increased in the CNS of model mice treated with both drugs. Tariquidar and bortezomib treated mice also lived longer and had improved motor function compared with tariquidar-alone, bortezomib-alone, and vehicle treated counterparts. These data suggest that P-gp inhibition increases the CNS bioavailability of a proteasome inhibitor, which is of particular interest in the development of therapeutics for neurological disorders.
Results

Bortezomib is transported by P-gp
In order to verify that bortezomib is transported by P-gp and not by other transporters (O'Connor et al., 2013) we used MCF-7 and HEK293 cells that express P-gp, BCRP, or no drug efflux transporters and tested bortezomib's transport. MCF-7 cells do not express high levels of P-gp or BCRP at baseline; however selection with flavopiridol increases BCRP expression (Robey et al., 2001 ) and selection with etoposide increases P-gp levels (Schneider et al., 1994) . We therefore generated MCF-7 cells that expressed P-gp or BRCP using these selection processes. Since we were interested in the basal activity of the proteasome in the treated cells we tested several different cell lysate protein concentrations to find an appropriate concentration at which chymotrypsinlike activity of the endogenous proteasome was measurable (Supplemental Fig. 1a) . The chymotrypsin-like activity of the endogenous proteasome of 70 μg of cell lysate was well above the residual activity seen with no substrate or no lysate negative controls, but less than the maximal amount seen when excess purified proteasome was tested. The chymotrypsin-like activity of the proteasome of the drug naive cells in the presence of bortezomib and tariquidar was similar to bortezomib alone (n = 6, p N 0.05) (Fig. 1a) . However, MCF-7 cells that had been selected to express P-gp showed further reduction of chymotrypsin-like activity of the proteasome with tariquidar pretreatment (1 μM, 15 min) before bortezomib treatment (0.5 μM, 30 min) (n = 6, p b 0.05) (Fig. 1b) . However, pre-treatment with tariquidar did not significantly increase the inhibition of the proteasome of the BCRP overexpressing cells when compared with bortezomib alone treatment (n = 6, p N 0.05) (Fig. 1c) .
HEK293 cells do not typically express P-gp (Robey et al., 2011) ; bortezomib (0.5 μM, 30 min) inhibited the chymotrypsin-like activity of the proteasome (n = 6, p b 0.01) and there was no additive effect when the cells were pretreated with tariquidar (n = 6, p N 0.05) (Supplemental Fig. 2a) . Cells that stably express P-gp showed increased inhibition to the chymotrypsin-like activity of the proteasome when treated with tariquidar (15 min, 1 μM) before bortezomib treatment (0.5 μM, 30 min) (n = 6, p b 0.05) (Supplemental Fig. 2b ). Tariquidar treatment alone does not inhibit the chymotrypsin-like activity of the proteasome in either the MCF-7 cells (Fig. 1a, b, c) or the HEK cells (Supplemental Fig. 2c ). Together, these data indicated that bortezomib was a substrate of P-gp, but not of BRCP.
2.2. Bortezomib levels and proteasome inhibition are enhanced in spinal cord of P-gp1a/b BCRP knockout mice compared with control mice
We verified that bortezomib was transported by P-gp in vivo by treating P-gp1a/b/BCRP triple knockout mice (FVB.129P2-Abcb1a-tm1Bor :Acb1b tm1Bor :Abcg2 tm1Ahs N7) or the parental strain (FVB) mice with a single dose of bortezomib (Velcade) by intraperitoneal (i.p.) injection (0.15 mg/kg). Mice carry two P-gp genes, unlike humans, and both genes must be knocked down to prevent drug extrusion from the cytoplasmic membrane (Croop et al., 1989) . Tariquidar is a known inhibitor of both P-gp and BCRP (Bauer et al., 2013) and these triple knockout mice most closely mimic the anticipated effects of tariquidar treatment.
We measured the levels of bortezomib in the CNS by liquid chromatography-tandem mass spectrometry (LCMS/MS) and observed that bortezomib in the spinal cord was 3.2 fold higher 1 h post injection in the P-gp1a/b:BCRP knockout mouse spinal cords (257.9 ± 79.1 ng/mg tissue) compared with the spinal cords of the parental strain mice (38.7 ± 0.9 ng/mg tissue) (p b 0.01) (Fig. 2a) . Additionally, the chymotrypsin-like activity of the proteasome was decreased in the spinal cord lysates 1 h post-injection of the bortezomib-treated P-gp1a/b/BCRP knockout mice compared with the bortezomib-treated parental strain mice (p b 0.05) (Fig. 2b) . A single dose of bortezomib (0.15 mg/kg) did not alter the expression of the proteasome subunit responsible for chymotrypsin-like catalytic activity PSMB5 (Supplemental Fig. 3 ).
Bortezomib levels in SMA mouse CNS increase and proteasome activity is inhibited with co-administration of an ABC transporter inhibitor
Having shown that bortezomib was a substrate of P-gp in cultured cells and in mice we next sought to determine whether the ABC transporter inhibitor tariquidar could increase the CNS penetrance of bortezomib and slow SMN degradation in SMA model mice. SMA pups (hSMN2:Δ7SMN:smn −/−) were treated by i.p. injections of bortezomib (0.15 mg/kg) starting at post-natal day 4 (P4) and continued every other day until P8. At P8 the dose of bortezomib was decreased to 0.075 mg/kg, due to diarrhea observed in preliminary studies (outlined in Kwon et al., 2011 ) from extended treatment with the higher dose of bortezomib, and the mice were subsequently treated every other day until P12. In addition, pups were administered (99% pure by high performance liquid chromatography) tariquidar (i.p., 6.5 or 13 mg/kg) 15 min before bortezomib administration. The bortezomib and tariquidar combination treatment paradigm used here did not alter the typical weight gain of control mice compared to tariquidar-only treatment and untreated controls (Supplemental Fig. 4) , and no early deaths were seen.
Mice were sacrificed at P12, and levels of bortezomib in the brains of bortezomib-only and bortezomib and tariquidar-treated mice were measured by LCMS/MS. Bortezomib levels in the brain were nearly undetectable in bortezomib-only treated mice (106 ± 28 ng/mg tissue), but increased 4.5 fold when bortezomib was co-administered with Fig. 2 . Bortezomib penetrates the BBB of PGP1a/b:BCRP knockout mice, but not the parental strain control mice (FVB). Mice at P12 were injected with bortezomib (0.15 mg/kg) and sacrificed 1 h later. The spinal cords were removed and bortezomib levels were analyzed with LCMS/MS (a). The chymotrypsin-like activity of the endogenous proteasome in the spinal cords was assessed by analyzing the cleavage of the fluorogenic peptide Suc-LLVY-AMC (b) when it was added to spinal cord lysate. Values represent, respectively, bortezomib concentration or chymotrypsin-like activity relative to wild type control ± SEM,*p b 0.01. Fig. 3 . Bortezomib penetrates the BBB and BSCB when mice are pre-treated with tariquidar. Mice at P4 were given tariquidar (6.5 or 13 mg/kg) or vehicle (100% DMSO, 1 μL/g) 15 min before bortezomib (0.15 mg/kg-0.075 mg/kg) or vehicle (Ringer's solution, 1 μL/g) i.p. injection every other day and sacrificed at P12. The brains were analyzed for bortezomib concentration using LCMS/MS (a). The chymotrypsin-like activity of the proteasome in the brains was assessed by examining the cleavage of the fluorogenic peptide Suc-LLVY-AMC (b) when it was added to the brain lysate. Values represent, respectively, bortezomib concentration or chymotrypsin-like activity relative to bortezomib-only treated control ± SEM,*p b 0.01. tariquidar (455 ± 118 ng/mg tissue) (p b 0.01) (Fig. 3a) . Similar increases in bortezomib penetrance occurred in spinal cord tissue. However, the small tissue volumes of the spinal cord from late stage SMA disease mice led to higher levels of variability, and a statistically significant difference was not observed in the spinal cord samples (Supplemental Fig. 5 ). In addition, the chymotrypsin-like activity of the proteasome in the brain was reduced in bortezomib and tariquidar-treated animals compared with bortezomib-only treated animals (p b 0.01) (Fig. 3b). 2.4. Bortezomib increases SMN protein levels in the SMA mouse CNS when paired with a P-gp inhibitor
Since we observed increased penetrance of bortezomib into the CNS with tariquidar pre-treatment, we investigated whether SMN levels increased as well. We reported previously that levels of SMN increased in peripheral tissue in bortezomib-treated mice, but no change was seen in CNS tissue (Kwon et al., 2011) . Co-administration of two different doses of tariquidar (6.5 and 13 mg/kg) with bortezomib increased SMN protein levels in the brain, but the increase in SMN protein only reached statistical significance with the 13 mg/kg dose of tariquidar (n = 6, p b 0.05) (Fig. 4a,b) . Similar SMN protein increases were seen in spinal cord tissue although the small tissue volumes from late stage SMA disease mice led to higher levels of variability, and a statistically significant difference was not observed (Supplemental Fig. 6 ).
Bortezomib enhances motor function in SMA model mice when paired with a P-gp inhibitor
Since there were increases to SMN protein levels in the CNS we asked whether the CNS penetrance would also improve the functional benefit of bortezomib. SMA mice were treated as described above, but with treatment continuing until mice reached pre-specified conditions for euthanasia (30% weight loss or inability to right after 30 s). The SMA mice begin to show difficulty with righting at day 10 leading to an inability to right within 30 s by day 14 with the median age of death 13. days . We detected an improvement in the righting times of mice treated with bortezomib and tariquidar over bortezomib alone (n = 10, p b 0.05 starting at day 8) (Fig. 5a ). Combining bortezomib with tariquidar pre-treatment further extended survival Fig. 4 . Bortezomib with tariquidar pre-treatment increases SMN protein levels in the CNS. Mice were treated with tariquidar (6.5 mg/kg or 13 mg/kg) or vehicle (100% DMSO, 1 μL/g) 15 min before bortezomib (0.15 mg/kg) or vehicle (Ringer's solution, μL/g) i.p. injection every other day starting at P4 and sacrificed at P12. 13 mg/kg tariquidar increased SMN protein levels in the brain (b), while the SMN increase with 6.5 mg/kg tariquidar (a) was not significantly different from bortezomib alone. Brain tissue was removed and protein lysates from these tissues were isolated to examine SMN protein levels. The ratio of SMN to actin protein levels was determined by a densitometry analysis. Values represent mean ± SEM. *p b 0.05, n = 6. by 1.5 day compared with bortezomib treatment alone (n = 13, p b 0.05) (Fig. 5b) .
Discussion
The BBB and BSCB restrict the ability of drugs to reach their intended site of action in the CNS and thus present a major challenge to the treatment of neurological disorders. This has prompted interest in developing novel drug delivery strategies to improve therapeutic access to the CNS (Pardridge, 2012) . In this study we aimed to show that (i) P-gp impacted the efficacy of bortezomib in our model systems and that (ii) inhibiting P-gp improved the CNS delivery and efficacy of a pharmaceutical agent in a model of motor neuron disease. We showed that proteasome function is inhibited when P-gp was either deleted or inhibited in the presence of bortezomib. Importantly, bortezomib inhibition of the proteasome increased steady-state SMN protein levels in the CNS when P-gp was inhibited. Additionally, motor function and survival were enhanced with SMN stabilization in the CNS.
It has previously been reported that bortezomib is transported by P-gp (Nakamura et al., 2007; Rumpold et al., 2007; Lu et al., 2010; O'Connor et al., 2013) , primarily in the context of cancer multidrug resistance (Jung et al., 2004) . Interestingly a silent polymorphism in P-gp, MDR1 C3435T, confers increased latency to relapse and higher bortezomib efficacy in human multiple myeloma (Buda et al., 2009 (Buda et al., , 2010 . While BCRP has also been implicated in bortezomib efflux (Gil et al., 2007; Wiberg et al., 2009 ) it has been stated by others that P-gp is the primary transporter responsible for bortezomib efflux (O'Connor et al., 2013) . We used the P-gp and BCRP inhibitor tariquidar to prevent bortezomib efflux (Kannan et al., 2011) . While the contribution of other efflux pumps appears unlikely it has also been postulated that the decrease in efficacy of bortezomib in patients is due to other mechanisms such as upregulation of PSMB5, a subunit of the proteasome (Lu et al., 2008 (Lu et al., , 2009 . Using genetic models and pharmacological agents we confirm that bortezomib is indeed a substrate of P-gp, independent of PSMB5 expression.
We showed previously that bortezomib stabilizes SMN protein levels in peripheral tissue (Kwon et al., 2011) . We showed here that bortezomib is a potent proteasome inhibitor in the CNS when allowed to cross the BBB. Bortezomib activity in the CNS stabilizes SMN protein levels and improves SMA disease manifestations in mice. It has been established that increasing SMN protein levels through induction of the SMN2 gene or altering splicing improves SMA pathology in mouse models (Foust et al., 2010; Hua et al., 2011; Cherry et al., 2013) . Stabilizing SMN protein by blocking protein degradation in peripheral tissue improves motor function of SMN mice, but does not extend survival, reinforcing the critical role of SMN in the CNS. We demonstrated here that bortezomib was normally excluded from the CNS and that increasing bortezomib levels in the CNS had positive effects on SMA pathology in mice. However, the survival benefit of bortezomib was less robust than that seen with other compounds that increased SMN to similar levels. One possibility is that off-target toxicity associated with bortezomib prevented full effects of the SMN stabilization. Indeed, it has been shown in human patients that bortezomib can cause peripheral neuropathy (Argyriou et al., 2008) . It has been determined that bortezomib also inhibits HtrA2/Omi, an ATP-dependent serine protease in mitochondria which protects neurons from undergoing apoptosis (Arastu-Kapur et al., 2011) , and this likely accounts for the peripheral neuropathy. Importantly, increasing specificity dramatically decreased proteasome inhibitor cytotoxicity in cultured cells (Screen et al., 2010) . The next-generation proteasome inhibitors currently undergoing clinical consideration can achieve stronger inhibition of chymotrypsin-like activity of the proteasome in vivo and do not inhibit HtrA2.
Recently, it was shown that the amyotrophic lateral sclerosis (ALS) drug riluzole has increased efficacy in an animal model of familial ALS when co-administered with an ABC transporter inhibitor elacridar (Jablonski et al., 2014) . Additionally, co-administration of tariquidar with the anti-seizure drug pentobarbital improves anti-epileptic activity in previously drug resistant rats (Brandt et al., 2006) . Any therapy under development intended to be active in the CNS must be able to traverse the BBB and BSCB and not be transported by P-gp. There are no current FDA-approved proteasome inhibitors reported to be CNS permeable. The drug efflux transporters represent a formidable obstacle when developing new therapies for neuromuscular and neurodegenerative disorders. Our results show that pharmacological inhibition of P-gp can enhance CNS penetrance of bortezomib. Inhibition of P-gp by tariquidar has been demonstrated in humans with PET imaging, using IV administration (Bauer et al., 2015; Kreisl et al., 2015) . Our study and the study with the ALS model reported by Jablonski et al. demonstrate that co-administration of P-gp inhibitors with CNS treatments can improve their efficacy.
Materials and methods
Mice
Studies were approved by the National Institute of Neurological Diseases and Stroke Animal Care and Use Committee and done in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Transgenic SMA mice on the FVB background (hSMN2/Δ7SMN/mSmn−/−) were purchased from Jackson Laboratories. The animals were genotyped using polymerase chain reaction on tail DNA using two sets of primers against mouse smn and beta- galactosidase to ensure that the mouse smn gene is knocked out (Kernochan et al., 2005 ) were a kind gift from Dr. Robert Innis, NIMH. The animals were genotyped using polymerase chain reaction on ear punch tissues to ensure that they lacked both isoforms of P-gp1 and BCRP.
For biochemical studies, the mice were anesthetized with isofluorane and sacrificed by cervical dislocation. Spinal cords, brains, and livers were dissected, flash-frozen in liquid nitrogen, and stored at −80°C.
For survival studies, litters were maintained and kept with the mother until euthanasia with no supplementation. Mice that lost 30% of their body weight and were unable to right themselves after 30 s were euthanized as mandated by the NINDS ACUC committee.
Drug treatment
Bortezomib was dissolved in sterile Ringer's solution to a concentration of 0.15 μg/μL or 0.075 μg/μL. Pups at postnatal day 4 (P4) and at day 6 (P6) were administered 1 μL of 0.15 μg/μL bortezomib per gram (for a concentration of 0.15 mg/kg) intraperitoneally. We had found that 0.15 mg/kg was the highest tolerated in neonatal mice (Kwon et al., 2011) . From P8 to P12 pups were injected every other day with 1 μL of 0.075 μg/μL bortezomib per gram (for a concentration of 0.075 mg/kg). Control animals received equal volumes of Ringer's saline. 99% pure by HPLC tariquidar was dissolved in 100% DMSO to a concentration of 6.5 μg/μL or 13 μg/μL. Pups at P4 were administered 1 μL of tariquidar per gram every other day for a total concentration of 6.5 mg/kg or 13 mg/kg in a manner similar to bortezomib. To maximize the dose of bortezomib crossing the BBB, mice were given tariquidar 15 min before bortezomib. Control animals received equal volumes of DMSO.
Motor function analysis
For one-time measures, pups were weighed and tested for their ability to right themselves. Righting time was defined as the average of four trials of the time required for a pup to turn over after being placed on its back (maximum 30 s) (Cherry et al., 2013) .
Protein extraction and quantification
Spinal cords were homogenized and incubated in 500 μL of lysis buffer (0.1% NP-40 and 0.5% sodium deoxycholate) for 15 min on ice, and the collected lysates were sonicated for 3 pulses of 10 s before another 15 min incubation on ice. Supernatants were collected after 15 min centrifugation at 14,000 g at 4°C and stored at −80°C. Protein concentrations were determined by the Bradford Protein Assay kit (Bio-Rad) according to the manufacturer's protocol.
Western blotting
Protein lysates (50 μg) were run and separated on a 10% SDS-PAGE gel electrophoresis gel and transferred to a PVDF membrane. These membranes were then probed with a mouse anti-SMN antibody (BD Transduction Laboratories, diluted 1:1000), and a mouse anti-β-actin antibody (Sigma-Aldrich, diluted 1:10,000) or a mouse anti-B-tubulin (Sigma-Aldrich, 1:1000)) and followed by incubation with goat HRP-conjugated anti-mouse secondary antibody. Blots were developed using Clarity ECL (BioRad). All Western blot images were collected with Chemidoc (Bio-Rad).
In vitro transport
HEK293 cells stably transfected with either an empty vector or P-gp were cultured in DMEM + 10%FBS and geneticin (Life Technologies, 1:1000). The cells were plated in 6-well plates, 2 × 10 6 cells per well.
The cells were treated with tariquidar (15 min, 1 μM) then treated with bortezomib (30 min, 0.5 μM). The cells were then collected in 500 μL lysis buffer (0.1% NP-40 and 0.5% sodium deoxycholate) for 15 min on ice. Protein concentrations were determined by the Bradford Protein Assay kit (Bio-Rad) according to the manufacturer's protocol.
Proteasome assay
Chymotrytic-like activity of the proteasome was measured by mixing (70 μg) tissue or cell homogenate with 50 μM fluorogenic peptide Suc-LLVY-AMC (succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin) (Enzo Life Sciences, Farmingdale, NY) in a final volume of 100 μL. The reaction buffer consisted of 50 mM Tris-HCl (pH 7.8), 20 mM KCl, 5 mM MgCl 2 , and 1 mM dithiothreitol. The mixture was incubated at 37°C for 30 min, and the released fluorogenic AMC was measured at 360-nm excitation and 460-nm emission. Epoxomicin (or MG132)-insensitive activity was subtracted from the final activity calculation. Substrate only or lysate only controls with no residual fluorescence signal and incubation with excess purified proteasome with multifold higher levels of signal were included in every assay.
Liquid chromatography tandem mass spectrometry (LCMS/MS)
Flash frozen spinal cord tissue samples were mixed with PBS (pH 7.2, 1:1 ratio) and homogenized with a pestle-type homogenizer. The homogenate was treated with 2 volumes of acetonitrile to precipitate the proteins, and the supernatant was analyzed by LCMS/MS. Samples were created for calibration and quality control with a working dilution of bortezomib in warfarin at 50 times the final concentration, and this was serially diluted to make the standard samples. These samples were diluted 31-fold into blank tissue extract and processed as above.
The signal was optimized for bortezomib by electrospray negative ionization (ESI) mode. A MS2 targeted SIM scan was used to optimize the precursor ion, and a product ion analysis was used to identify the best fragment for analysis and to optimize the collision energy.
Samples were analyzed with an ABI3000 mass spectrometer coupled with a Shimadzu HPLC and a Sil-HTc chilled autosampler, all controlled by Analyst software (ABI). After separation on a C18 reverse phase HPLC column (Agilent, Waters, or equivalent) mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in acetonitrile.
Statistics
All analysis was carried out by investigators who were blinded to the drug conditions or mouse genotype. All statistics were carried out using the GraphPad Prism software package (version 6; GraphPad Software) and compared with either two-tailed Student's t-test or one-way ANOVA followed by the Newman-Keuls multiple comparison post hoc tests. p ≤ 0.05 was considered significant.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.nbd.2016.01.008.
